Scarica l'app Stockscreener
1.33
5.67%
-0.08
Dopo l'orario di chiusura:
1.34
0.01
+0.75%
Precedente Chiudi:
$1.41
Aprire:
$1.41
Volume 24 ore:
198.74K
Relative Volume:
0.49
Capitalizzazione di mercato:
$167.99M
Reddito:
-
Utile/perdita netta:
$-70.78M
Rapporto P/E:
-2.375
EPS:
-0.56
Flusso di cassa netto:
$-61.27M
1 W Prestazione:
+9.02%
1M Prestazione:
+57.42%
6M Prestazione:
+93.15%
1 anno Prestazione:
-48.85%
Intervallo 1D:
$1.28
$1.4532
Intervallo di 1 settimana:
$1.21
$1.6301
Portata 52W:
$0.62
$2.9181
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Nome
Nautilus Biotechnology Inc
Settore
Industria
Telefono
206-333-2001
Indirizzo
2701 EASTLAKE AVE EAST, SEATTLE
Confronta NAUT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
1.33 | 178.09M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-05 | Downgrade | Goldman | Neutral → Sell |
| 2024-06-27 | Iniziato | Guggenheim | Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2022-01-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-02 | Iniziato | Cowen | Outperform |
| 2021-08-04 | Iniziato | Goldman | Neutral |
| 2021-07-13 | Iniziato | Jefferies | Buy |
Mostra tutto
Nautilus Biotechnology Inc Borsa (NAUT) Ultime notizie
Identifying reversal signals in Nautilus Biotechnology Inc.Weekly Loss Report & Accurate Technical Buy Alerts - newser.com
Why Nautilus Biotechnology Inc. stock is considered a top pickQuarterly Earnings Summary & Weekly Momentum Stock Picks - newser.com
Strategies to average down on Nautilus Biotechnology Inc.July 2025 Drop Watch & Real-Time Volume Analysis - newser.com
How to recover losses in Nautilus Biotechnology Inc. stock2025 Top Decliners & Community Consensus Trade Signals - newser.com
Long term hold vs stop loss in Nautilus Biotechnology Inc.Market Activity Report & Real-Time Chart Breakout Alerts - newser.com
Has Nautilus Biotechnology Inc. found a price floorJuly 2025 Fed Impact & Stepwise Trade Signal Guides - newser.com
Is Nautilus Biotechnology Inc. stock oversold or undervaluedWeekly Trading Summary & High Accuracy Trade Alerts - newser.com
How geopolitical tensions affect Nautilus Biotechnology Inc. stockJuly 2025 Review & Long Hold Capital Preservation Plans - newser.com
Can Nautilus Biotechnology Inc. stock weather global recession2025 Market Overview & Reliable Volume Spike Alerts - newser.com
Why Nautilus Biotechnology Inc. stock is recommended by analystsJuly 2025 Review & Technical Buy Zone Confirmation - newser.com
Earnings visualization tools for Nautilus Biotechnology Inc.July 2025 Outlook & Free Safe Capital Growth Stock Tips - newser.com
Nautilus Biotech Earnings Call Highlights Strategic Progress - TipRanks
Nautilus Biotechnology Inc (NAUT) Q3 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
How Nautilus Biotechnology Inc. stock reacts to oil pricesWeekly Gains Report & Growth Focused Entry Point Reports - newser.com
Nautilus Biotechnology Faces Nasdaq Delisting Risk Amid Compliance Challenges - TipRanks
How Nautilus Biotechnology Inc. stock performs in rate cut cycles2025 Year in Review & Daily Stock Trend Reports - newser.com
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2025 Earnings Call Transcript - Insider Monkey
Nautilus anticipates early access Tau assay launch in H1 2026 while strengthening proteoform platform partnerships - MSN
Nautilus Biotechnology Advances Toward 2026 Commercial Launch - TipRanks
Nautilus Biotechnology And 2 Other Promising Penny Stocks - Yahoo Finance
Nautilus Biotechnology Narrows Losses And Gains Analyst Confidence - Finimize
Why Nautilus Biotechnology Inc. stock is a must watch in 2025July 2025 Earnings & Accurate Intraday Trading Signals - Fundação Cultural do Pará
Does Nautilus Biotechnology Inc. stock trade at a discount to peersWeekly Stock Report & AI Optimized Trading Strategy Guides - Fundação Cultural do Pará
Earnings call transcript: Nautilus Biotechnology beats Q3 2025 EPS expectations - Investing.com
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results - Investing News Network
Nautilus Biotechnology, Inc. Q3 Loss Decreases, Beats Estimates - Nasdaq
Will Nautilus Biotechnology Inc. stock outperform value stocksWeekly Volume Report & AI Powered Market Entry Ideas - newser.com
Nautilus Biotechnology Incquarterly net loss per share $0.11filing - MarketScreener
Nautilus Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Growth Review: Will Nautilus Biotechnology Inc. stock deliver shareholder valueWeekly Trade Summary & High Win Rate Trade Tips - Fundação Cultural do Pará
Published on: 2025-10-28 04:14:00 - newser.com
Is this a good reentry point in Nautilus Biotechnology Inc.July 2025 Decliners & Expert Approved Momentum Trade Ideas - newser.com
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025 - Investing News Network
Published on: 2025-10-28 01:43:09 - newser.com
Nautilus Biotechnology Inc Azioni (NAUT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):